MacroGenics Stock (NASDAQ:MGNX)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$3.48

52W Range

$2.95 - $21.88

50D Avg

$3.67

200D Avg

$8.23

Market Cap

$205.86M

Avg Vol (3M)

$656.97K

Beta

2.08

Div Yield

-

MGNX Company Profile


MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

339

IPO Date

Oct 10, 2013

Website

MGNX Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Revenue From Government Agreements$1.56M$1.92M$1.80M
Contract Manufacturing$9.83M$13.99M-
Product$17.94M$16.73M$12.35M
Revenue From Collaborative Agreements$28.99M$119.30M$63.29M

Fiscal year ends in Dec 23 | Currency in USD

MGNX Financial Summary


Dec 23Dec 22Dec 21
Revenue$58.75M$151.94M$75.64M
Operating Income$-168.24M$-121.42M$-202.79M
Net Income$-9.06M$-120.02M$-190.86M
EBITDA$-168.24M$-121.42M$-202.79M
Basic EPS-$-1.95$-3.18
Diluted EPS-$-1.95$-3.18

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Nov 05, 24 | 7:01 PM
Q1 24May 09, 24 | 12:00 AM
Q4 23Mar 07, 24 | 11:30 PM

Peer Comparison


TickerCompany
NGMNGM Biopharmaceuticals, Inc.
PMVPPMV Pharmaceuticals, Inc.
CGEMCullinan Oncology, Inc.
ZNTLZentalis Pharmaceuticals, Inc.
MLYSMineralys Therapeutics, Inc.
DAWNDay One Biopharmaceuticals, Inc.
EWTXEdgewise Therapeutics, Inc.
IPSCCentury Therapeutics, Inc.
SNDXSyndax Pharmaceuticals, Inc.
TYRATyra Biosciences, Inc.
INZYInozyme Pharma, Inc.
ANTXAN2 Therapeutics, Inc.
CCCCC4 Therapeutics, Inc.
GLUEMonte Rosa Therapeutics, Inc.
PHVSPharvaris N.V.
PEPGPepGen Inc.
NKTXNkarta, Inc.
MOLNMolecular Partners AG
KZRKezar Life Sciences, Inc.
PTGXProtagonist Therapeutics, Inc.